ES2170815T3 - Potenciador de agente antitumoral que comprende un antagonista de il-6. - Google Patents

Potenciador de agente antitumoral que comprende un antagonista de il-6.

Info

Publication number
ES2170815T3
ES2170815T3 ES95942318T ES95942318T ES2170815T3 ES 2170815 T3 ES2170815 T3 ES 2170815T3 ES 95942318 T ES95942318 T ES 95942318T ES 95942318 T ES95942318 T ES 95942318T ES 2170815 T3 ES2170815 T3 ES 2170815T3
Authority
ES
Spain
Prior art keywords
antagonist
potential
antitumoral agent
understanding
agent understanding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95942318T
Other languages
English (en)
Other versions
ES2170815T5 (es
Inventor
Osamu Yoshida
Youichi Mizutani
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=18336838&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2170815(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Application granted granted Critical
Publication of ES2170815T3 publication Critical patent/ES2170815T3/es
Publication of ES2170815T5 publication Critical patent/ES2170815T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Peptides Or Proteins (AREA)

Abstract

POTENCIADOR PARA AGENTES ANTITUMORALES COMO POR EJEMPLO, COMPUESTOS DE PLATINO TALES COMO CISPLATINO Y CARBOPLATINO, MITOMICINA C, ETC., QUE INCLUYE UN ANTAGONISTA DE INTERLEUCINA 6 (IL - 6) TALES COMO UN ANTICUERPO FRENTE A IL - 6, UN ANTICUERPO FRENTE AL RECEPTOR DE IL - 6, UN ANTICUERPO FRENTE A LA PROTEINA GP130, ETC.
ES95942318T 1994-12-29 1995-12-28 Uso de un anticuerpo PM-1 o de un anticuerpo MH166 para potenciar el efecto antitumoral de cisplatino o carboplatino Expired - Lifetime ES2170815T5 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP34042594 1994-12-29
JP34042594 1994-12-29
PCT/JP1995/002769 WO1996020728A1 (en) 1994-12-29 1995-12-28 Antitumor agent potentiator comprising il-6 antagonist

Publications (2)

Publication Number Publication Date
ES2170815T3 true ES2170815T3 (es) 2002-08-16
ES2170815T5 ES2170815T5 (es) 2012-11-14

Family

ID=18336838

Family Applications (1)

Application Number Title Priority Date Filing Date
ES95942318T Expired - Lifetime ES2170815T5 (es) 1994-12-29 1995-12-28 Uso de un anticuerpo PM-1 o de un anticuerpo MH166 para potenciar el efecto antitumoral de cisplatino o carboplatino

Country Status (11)

Country Link
US (1) US6086874A (es)
EP (1) EP0800829B2 (es)
JP (2) JP4079461B2 (es)
KR (1) KR100252743B1 (es)
CN (1) CN1075387C (es)
AT (1) ATE214602T1 (es)
AU (1) AU704723B2 (es)
CA (1) CA2209124C (es)
DE (1) DE69525971T3 (es)
ES (1) ES2170815T5 (es)
WO (1) WO1996020728A1 (es)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4503939A (en) * 1983-08-19 1985-03-12 Westinghouse Electric Corp. Elevator system
ES2312184T3 (es) 1997-03-21 2009-02-16 Chugai Seiyaku Kabushiki Kaisha Agentes preventivos terapeuticos para el tratamiento de esclerosis multiple, que contienen anticuerpos anti-receptores de il-6 antagonistas.
IT1291932B1 (it) * 1997-06-20 1999-01-21 Angeletti P Ist Richerche Bio Composizioni farmaceutiche antitumorali capaci anche di ridurre la farmacoresistenza in cellule tumorali, in particolare di carcinoma
US20020187150A1 (en) * 1997-08-15 2002-12-12 Chugai Seiyaku Kabushiki Kaisha Preventive and/or therapeutic agent for systemic lupus erythematosus comprising anti-IL-6 receptor antibody as an active ingredient
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
US6468528B1 (en) * 1999-02-01 2002-10-22 Amgen Canada Inc. Materials and methods to inhibit Hodgkin and Reed Sternberg cell growth
UA80091C2 (en) * 2001-04-02 2007-08-27 Chugai Pharmaceutical Co Ltd Remedies for infant chronic arthritis-relating diseases and still's disease which contain an interleukin-6 (il-6) antagonist
EP1459762B1 (en) * 2001-11-02 2008-07-02 Yoshiko Yasuda Use of emp9 for the prevention of proliferative organ diseases
IL161630A0 (en) * 2001-11-06 2004-09-27 Applied Research Systems Methods of treating endometreosis
RU2318829C2 (ru) 2001-11-14 2008-03-10 Сентокор, Инк. Антитела против il-6, композиции, способы и применение
ES2382800T3 (es) * 2002-01-18 2012-06-13 Zymogenetics, Inc. Multímeros Zcytor17 receptores de citocinas
EP3192528A1 (en) 2002-02-14 2017-07-19 Chugai Seiyaku Kabushiki Kaisha Formulation of anti-il6r antibody-containing solutions comprising a sugar as a stabilizer
EP1498137A1 (en) * 2002-04-25 2005-01-19 Chugai Seiyaku Kabushiki Kaisha Remedy for lung cancer
WO2004045507A2 (en) * 2002-11-15 2004-06-03 Centocor, Inc. Anti-angiogenic uses of il-6 antagonists
GB2401040A (en) * 2003-04-28 2004-11-03 Chugai Pharmaceutical Co Ltd Method for treating interleukin-6 related diseases
US20050100550A1 (en) * 2003-11-10 2005-05-12 Mohit Trikha Anti-angiogenic uses of IL-6 antagonists
WO2005090405A1 (ja) 2004-03-24 2005-09-29 Chugai Seiyaku Kabushiki Kaisha インターロイキン－６受容体に対するヒト型化抗体のサブタイプ
US8017395B2 (en) 2004-12-17 2011-09-13 Lifescan, Inc. Seeding cells on porous supports
PA8672101A1 (es) 2005-04-29 2006-12-07 Centocor Inc Anticuerpos anti-il-6, composiciones, métodos y usos
BRPI0611069A2 (pt) * 2005-05-06 2010-11-09 Zymogenetics Inc anticorpo monoclonal, anticorpo humanizado, fragmento de anticorpo, uso de um antagonista, e, hibridoma
EP1888123B1 (en) 2005-06-08 2013-01-09 Janssen Biotech, Inc. A cellular therapy for ocular degeneration
JP2007091710A (ja) * 2005-08-31 2007-04-12 Ishikawajima Harima Heavy Ind Co Ltd 薬、薬の誘導装置、磁気検出装置及び薬の設計方法
EA200870130A1 (ru) * 2005-12-30 2009-02-27 Мерк Патент Гмбх Антитела против ил-6, предотвращающие связывание с gp130 комплекса ил-6 и альфа-рецептора ил-6
US8741643B2 (en) 2006-04-28 2014-06-03 Lifescan, Inc. Differentiation of pluripotent stem cells to definitive endoderm lineage
NZ587107A (en) 2006-06-02 2012-05-25 Regeneron Pharma High affinity antibodies to human il-6 receptor
US8080248B2 (en) 2006-06-02 2011-12-20 Regeneron Pharmaceuticals, Inc. Method of treating rheumatoid arthritis with an IL-6R antibody
CN103705947A (zh) 2006-06-28 2014-04-09 株式会社Ihi 药物、药物引导装置、磁性检测装置和药物设计方法
AU2007282023B2 (en) 2006-08-03 2012-09-13 Vaccinex, Inc. Anti-IL-6 monoclonal antibodies and uses thereof
US20080081041A1 (en) * 2006-09-29 2008-04-03 Jeffrey Nemeth Method of Using IL6 Antagonists with Mitoxantrone for Prostate Cancer
US20090238825A1 (en) * 2007-05-21 2009-09-24 Kovacevich Brian R Novel rabbit antibody humanization methods and humanized rabbit antibodies
US9701747B2 (en) 2007-05-21 2017-07-11 Alderbio Holdings Llc Method of improving patient survivability and quality of life by anti-IL-6 antibody administration
US8178101B2 (en) 2007-05-21 2012-05-15 Alderbio Holdings Inc. Use of anti-IL-6 antibodies having specific binding properties to treat cachexia
US7906117B2 (en) * 2007-05-21 2011-03-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat cachexia, weakness, fatigue, and/or fever
KR20100028571A (ko) * 2007-05-21 2010-03-12 앨더 바이오파마슈티컬즈, 인코포레이티드 신규한 래빗 항체 인간화 방법 및 인간화된 래빗 항체
CN101754772B (zh) 2007-05-21 2015-08-19 奥尔德生物控股有限责任公司 针对il-6的抗体及其用途
US8404235B2 (en) * 2007-05-21 2013-03-26 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8252286B2 (en) 2007-05-21 2012-08-28 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8062864B2 (en) 2007-05-21 2011-11-22 Alderbio Holdings Llc Nucleic acids encoding antibodies to IL-6, and recombinant production of anti-IL-6 antibodies
US9080145B2 (en) 2007-07-01 2015-07-14 Lifescan Corporation Single pluripotent stem cell culture
US9096832B2 (en) 2007-07-31 2015-08-04 Lifescan, Inc. Differentiation of human embryonic stem cells
CN101246160B (zh) * 2007-09-06 2012-11-21 三峡大学 在体外用ELISA方法建立的IL-6/sIL-6R结合的分子模型
AU2008308163B2 (en) 2007-10-02 2013-03-21 Chugai Seiyaku Kabushiki Kaisha Therapeutic agents for graft-versus-host disease comprising interleukin 6 receptor inhibitor as active ingredient
ATE523585T1 (de) 2007-11-27 2011-09-15 Lifescan Inc Differenzierung menschlicher embryonaler stammzellen
KR101603109B1 (ko) 2007-12-07 2016-03-25 지모제넥틱스, 인코포레이티드 Ｉｌ-31에 특이적인 인간화된 항체 분자
PE20091174A1 (es) 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
US20090169484A1 (en) 2007-12-28 2009-07-02 Ihi Corporation Iron-salen complex
CA2959401C (en) 2008-02-21 2021-12-07 Centocor Ortho Biotech Inc. Methods, surface modified plates and compositions for cell attachment, cultivation and detachment
US8623648B2 (en) 2008-04-24 2014-01-07 Janssen Biotech, Inc. Treatment of pluripotent cells
US8188235B2 (en) * 2008-06-18 2012-05-29 Pfizer Inc. Antibodies to IL-6 and their uses
KR101651661B1 (ko) 2008-06-30 2016-08-26 얀센 바이오테크 인코포레이티드 만능 줄기 세포의 분화
MX2011004563A (es) 2008-10-31 2011-06-01 Centocor Ortho Biotech Inc Diferenciacion de celulas madre embrionarias humanas al linaje endocrino pancreatico.
CN102272291B (zh) 2008-10-31 2018-01-16 詹森生物科技公司 人胚胎干细胞向胰腺内分泌谱系的分化
KR20110094307A (ko) * 2008-11-13 2011-08-23 펨타 파마슈티컬스, 인크. 인간화된 항-ｉｌ-6 항체
WO2010058280A1 (ja) 2008-11-20 2010-05-27 株式会社Ihi 自己磁性金属サレン錯体化合物
PL2366022T3 (pl) 2008-11-20 2016-11-30 Sposoby i kompozycje do przyłączania i hodowli komórek na podłożach planarnych
PL2366021T3 (pl) 2008-11-20 2017-12-29 Janssen Biotech, Inc. Hodowla pluripotencjalnych komórek macierzystych na mikronośnikach
US8420089B2 (en) 2008-11-25 2013-04-16 Alderbio Holdings Llc Antagonists of IL-6 to raise albumin and/or lower CRP
US8337847B2 (en) 2008-11-25 2012-12-25 Alderbio Holdings Llc Methods of treating anemia using anti-IL-6 antibodies
US9452227B2 (en) 2008-11-25 2016-09-27 Alderbio Holdings Llc Methods of treating or diagnosing conditions associated with elevated IL-6 using anti-IL-6 antibodies or fragments
US9212223B2 (en) 2008-11-25 2015-12-15 Alderbio Holdings Llc Antagonists of IL-6 to prevent or treat thrombosis
US8323649B2 (en) 2008-11-25 2012-12-04 Alderbio Holdings Llc Antibodies to IL-6 and use thereof
US8992920B2 (en) 2008-11-25 2015-03-31 Alderbio Holdings Llc Anti-IL-6 antibodies for the treatment of arthritis
JO3672B1 (ar) 2008-12-15 2020-08-27 Regeneron Pharma أجسام مضادة بشرية عالية التفاعل الكيماوي بالنسبة لإنزيم سبتيليسين كنفرتيز بروبروتين / كيكسين نوع 9 (pcsk9).
JP5317690B2 (ja) 2008-12-27 2013-10-16 株式会社東芝 メモリシステム
EP2464666B1 (en) * 2009-07-15 2018-03-21 Eva Kovacs-Benke Combination of a human interleukin-6 antagonist and a human interleukin-6 receptor antagonist in therapy of tumour diseases
ES2693088T3 (es) 2009-07-20 2018-12-07 Janssen Biotech, Inc. Diferenciación de células madre embriónicas humanas
AU2010276402B2 (en) 2009-07-20 2014-07-03 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
KR20170118969A (ko) 2009-07-20 2017-10-25 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
CN104928336B (zh) 2009-10-26 2020-05-08 弗·哈夫曼-拉罗切有限公司 用于生产糖基化免疫球蛋白的方法
US9775921B2 (en) 2009-11-24 2017-10-03 Alderbio Holdings Llc Subcutaneously administrable composition containing anti-IL-6 antibody
EP2504032A4 (en) 2009-11-24 2013-06-19 Alderbio Holdings Llc IL-6 ANTAGONISTS FOR PREVENTING OR TREATING THROMBOSIS
AU2010333839C1 (en) 2009-12-23 2016-07-21 Janssen Biotech Inc. Differentiation of human embryonic stem cells
MX339669B (es) 2009-12-23 2016-06-02 Janssen Biotech Inc Diferenciacion de celulas madres embrionarias humanas.
JO3417B1 (ar) 2010-01-08 2019-10-20 Regeneron Pharma الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r
CN107189979B (zh) 2010-03-01 2021-05-04 詹森生物科技公司 纯化衍生自多能干细胞的细胞的方法
KR101986176B1 (ko) 2010-05-12 2019-06-05 얀센 바이오테크 인코포레이티드 인간 배아 줄기 세포의 분화
SI2578231T1 (sl) 2010-05-28 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Okrepljen protitumorski T celični odzivnik
WO2012030539A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
AU2011296381B2 (en) 2010-08-31 2016-03-31 Janssen Biotech, Inc. Differentiation of human embryonic stem cells
WO2012030540A2 (en) 2010-08-31 2012-03-08 Janssen Biotech, Inc. Differentiation of pluripotent stem cells
EP2787007A3 (en) 2010-11-08 2015-03-11 F. Hoffmann-La Roche AG Subcutaneously administered ANTI-IL-6 receptor antibody
CA2818814A1 (en) 2010-11-23 2012-05-31 Alder Biopharmaceuticals, Inc. Anti-il-6 antibodies for the treatment of anemia
MX385311B (es) 2011-01-28 2025-03-18 Sanofi Biotechnology Anticuerpos humanos frente a pcsk9 para su uso en métodos de tratamiento de grupos concretos de pacientes.
AR087305A1 (es) 2011-07-28 2014-03-12 Regeneron Pharma Formulaciones estabilizadas que contienen anticuerpos anti-pcsk9, metodo de preparacion y kit
TWI589299B (zh) 2011-10-11 2017-07-01 再生元醫藥公司 用於治療類風濕性關節炎之組成物及其使用方法
JO3370B1 (ar) 2011-11-10 2019-03-13 Regeneron Pharma طريقة لتثبيط نمو الورم عن طريق تثبيط مستقبل انترلوكين 6
US9388386B2 (en) 2011-12-22 2016-07-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into single hormonal insulin positive cells
CA2866590A1 (en) 2012-03-07 2013-09-12 Janssen Biotech, Inc. Defined media for expansion and maintenance of pluripotent stem cells
WO2013184888A1 (en) 2012-06-08 2013-12-12 Janssen Biotech, Inc. Differentiation of human embryonic stem cells into pancreatic endocrine cells
US10370644B2 (en) 2012-12-31 2019-08-06 Janssen Biotech, Inc. Method for making human pluripotent suspension cultures and cells derived therefrom
WO2014105543A1 (en) 2012-12-31 2014-07-03 Janssen Biotech, Inc. Culturing of human embryonic stem cells at the air-liquid interface for differentiation into pancreatic endocrine cells
RU2684215C2 (ru) 2012-12-31 2019-04-04 Янссен Байотек, Инк. Способ получения панкреатических эндокринных клеток (варианты) и способ увеличения выхода бета-клеток
RU2687379C2 (ru) 2012-12-31 2019-05-13 Янссен Байотек, Инк. Суспендирование и кластеризация плюрипотентных клеток человека с целью их дифференцировки в панкреатические эндокринные клетки
BR112015032960B1 (pt) 2013-07-04 2021-01-05 F. Hoffmann-La Roche Ag imunoensaio suprimido por interferência para detectar anticorpos anti-fármaco em amostras de soro
EP3068803B1 (en) 2013-11-12 2021-01-20 Sanofi Biotechnology Dosing regimens for use with pcsk9 inhibitors
US9017678B1 (en) 2014-07-15 2015-04-28 Kymab Limited Method of treating rheumatoid arthritis using antibody to IL6R
JP6588969B2 (ja) 2014-05-16 2019-10-09 ヤンセン バイオテツク，インコーポレーテツド 膵内分泌細胞内のｍａｆａ発現を強化するための小分子の使用
KR20240172758A (ko) 2015-08-18 2024-12-10 리제너론 파아마슈티컬스, 인크. 지단백질 분리반출술을 경험하고 있는 고지혈증을 갖는 환자를 치료하기 위한 항-pcsk9 억제성 항체
US11484591B2 (en) 2016-02-22 2022-11-01 Ohio State Innovation Foundation Chemoprevention using controlled-release formulations of anti-interleukin 6 agents, synthetic vitamin A analogues or metabolites, and estradiol metabolites
JP6705911B2 (ja) 2016-04-14 2020-06-03 ヤンセン バイオテツク，インコーポレーテツド 多能性幹細胞の中腸内胚葉細胞への分化
EP3596175A4 (en) 2017-03-17 2021-01-13 The Ohio State Innovation Foundation NANOPARTICLES FOR THE ADMINISTRATION OF CHEMOPREVENTIVE AGENTS
JP7542543B2 (ja) 2019-01-31 2024-08-30 サノフィ・バイオテクノロジー 若年性特発性関節炎を治療するための抗ｉｌ－６受容体抗体
US20220177978A1 (en) 2019-04-02 2022-06-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of predicting and preventing cancer in patients having premalignant lesions
CN114651010A (zh) 2019-04-24 2022-06-21 赛诺菲生物技术公司 类风湿性关节炎的诊断和治疗方法
KR20230061198A (ko) 2019-06-04 2023-05-08 사노피 바이오테크놀로지 류마티스성 관절염을 갖는 대상체에서 통증을 치료하기 위한 조성물 및 방법
JP2023508592A (ja) * 2019-12-31 2023-03-02 ペプチノフ 術後痛を予防又は治療するための医薬組成物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2598666B2 (ja) * 1987-10-19 1997-04-09 忠三 岸本 抗ヒトｂｃｄｆモノクローナル抗体
DE3939706C1 (es) * 1989-12-01 1991-03-21 Centre Regional De Transfusion Sanguine, Besancon, Fr
CA2103258A1 (en) * 1991-05-17 1992-11-18 Cory A. Waters Cytokine receptor targeted molecules for treatment of neoplastic cell growth

Also Published As

Publication number Publication date
CA2209124C (en) 2010-03-23
DE69525971D1 (de) 2002-04-25
EP0800829A1 (en) 1997-10-15
JP4812736B2 (ja) 2011-11-09
AU704723B2 (en) 1999-04-29
JPH08231433A (ja) 1996-09-10
DE69525971T2 (de) 2002-11-28
AU4356896A (en) 1996-07-24
WO1996020728A1 (en) 1996-07-11
ATE214602T1 (de) 2002-04-15
CA2209124A1 (en) 1996-07-11
EP0800829B2 (en) 2012-07-25
KR100252743B1 (ko) 2000-09-01
EP0800829A4 (en) 1999-12-22
ES2170815T5 (es) 2012-11-14
HK1001512A1 (en) 1998-06-26
EP0800829B1 (en) 2002-03-20
JP2008063344A (ja) 2008-03-21
DE69525971T3 (de) 2013-01-10
CN1075387C (zh) 2001-11-28
JP4079461B2 (ja) 2008-04-23
CN1174507A (zh) 1998-02-25
US6086874A (en) 2000-07-11

Similar Documents

Publication Publication Date Title
EP0800829A4 (en) AMPLIFIER OF AN ANTI-TUMO AGENT INCLUDING AN IL-6 ANTAGONIST
PT800519E (pt) Compostos moduladores de receptores de esteroides e metodos
DK1108435T3 (da) Forebyggende midler eller midler mod pancreatitis indeholdende anti-IL-6-receptor-antistoffer som den aktive bestanddel
ATE547119T1 (de) Präventives oder therapeutisches mittel mit einem il-6-antagonisten als wirkstoff für durch sensibilisierte t-zellen vermittelte erkrankungen
MX9704640A (es) Compuesto moduladores de los receptores de los esteroides y metodos para su preparacion.
AR004717A1 (es) Sal de bis-indolilmaleimida, formulacion farmaceutica que la comprende y su uso para la fabricacion de dicha formulacion
PT918774E (pt) Compostos moduladores do receptor para androgenio e metodos
BR9813957A (pt) Uso de antagonistas da vasopressina
NO983431L (no) Anti-klöemidler
EP1334731A4 (en) AGENT FOR PREVENTING OR TREATING PSORIASIS WITH AN IL-6 ANTAGONIST AS AN ACTIVE SUBSTANCE
TR199900090A2 (xx) Benzos�lfon t�revleri
BR9610875A (pt) Modulares rxr seletivos - dimeros e processos para seu uso
WO2001085158A3 (en) Anandamide and structurally related lipids as vanilloid receptor modulators
DK0852587T3 (da) Syntetiske peptider der inhiberer IL-6-aktivitet
DK0984963T3 (da) Hidtil ukendte forbindelser
PT1042320E (pt) Novos compostos que sao antagonistas de receptores duplos de ourinoceptores p2 e de proteina g 7-transmembranar
ATE282416T1 (de) Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen
ATE457317T1 (de) Chemokine rezeptor
MX9803791A (es) Intermediarios novedosos y su uso para preparar bisindolilmaleimidas n,n'-puenteadas.
ES2151118T3 (es) Evaluacion de substancias para aumentar y para modificar la actividad para la apc.
SG135907A1 (en) Analysis of agonist-activity and antagonist-activity to cytokinin receptor

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 800829

Country of ref document: ES